CoChat

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

Open access
Buse, John B., Rodbard, Helena W., Trescoli Serrano, Carlos, Luo, Junxiang, Ivanyi, Tibor, Bue-Valleskey, Juliana, Hartman, Mark L., Carey, Michelle A., Chang, Annette M. · 2016 · Diabetes Care
Cited by 82

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the efficacy and safety of basal insulin peglispro (BIL) versus insulin glargine in patients with type 2 diabetes (hemoglobin A1c [HbA1c] ≤9% [75 mmol/mol]) treated with basal insulin alone or with three or fewer oral antihyperglycemic medications. RESEARCH DESIGN AND METHODS: This 52-week, open-label, treat-to-target study randomized patients (mean HbA1c 7.42% [57.6 mmol/mol]) to BIL (n = 307) or glargine (n = 159). The primary end point was change from baseline HbA1c to 26 weeks (0.4% [4.4 mmol/mol] noninferiority margin). RESULTS: At 26 weeks, reduction in HbA1c was superior with BIL versus glargine (−0.82% [−8.9 mmol/mol] vs. −0.29% [−3.2 mmol/mol]; least squares mean difference −0.52%, 95% CI −0.67 to −0.38 [−5.7 mmol/mol, 95% CI −7.3 to −4.2; P < 0.001); greater reduction in HbA1c with BIL was maintained at 52 weeks. More BIL patients achieved HbA1c <7% (53 mmol/mol) at weeks 26 and 52 (P < 0.001). With BIL versus glargine, nocturnal hypoglycemia rate was 60% lower, more patients achieved HbA1c <7% (53 mmol/mol) without nocturnal hypoglycemia at 26 and 52 weeks (P < 0.001), and total hypoglycemia rates were lower at 52 weeks (P = 0.03). At weeks 26 and 52, glucose variability was lower (P < 0.01), basal insulin dose was higher (P < 0.001), and triglycerides and aminotransferases were higher with BIL versus glargine (P < 0.05). Liver fat content (LFC), assessed in a subset of patients (n = 162), increased from baseline with BIL versus glargine (P < 0.001), with stable levels between 26 and 52 weeks. CONCLUSIONS: BIL provided superior glycemic control versus glargine, with reduced nocturnal and total hypoglycemia, lower glucose variability, and increased triglycerides, aminotransferases, and LFC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc15-1531

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 23

  1. Raccah, 2007, When basal insulin therapy in type 2 diabetes mellitus is not enough--what next, Diabetes Metab Res Rev, 23, 257, 10.1002/dmrr.733 · DOI · Paper page
  2. Ross, 2011, Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes, Curr Med Res Opin, 27, 13, 10.1185/03007995.2011.621416 · DOI · Paper page
  3. Karl, 2013, Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus, Diabetes Obes Metab, 15, 622, 10.1111/dom.12072 · DOI
  4. Sinha, 2014, Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 16, 344, 10.1111/dom.12222 · DOI · Paper page
  5. Henry, 2014, Basal insulin peglispro demonstrates preferential hepatic vs. peripheral action relative to insulin glargine in healthy subjects, Diabetes, 63, A226
  6. Moore, 2014, Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism, Diabetes, 63, 494, 10.2337/db13-0826 · DOI · Paper page
  7. Mudaliar, 2015, Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. insulin glargine (GL) in patients with type 1 diabetes mellitus, Diabetologia, 58, S1
  8. Eaton, 1983, Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion, J Clin Endocrinol Metab, 56, 1294, 10.1210/jcem-56-6-1294 · DOI · Paper page
  9. Herring, 2014, Hepatoselectivity and the evolution of insulin, Diabetes Obes Metab, 16, 1, 10.1111/dom.12117 · DOI
  10. Bergenstal, 2012, A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes, Diabetes Care, 35, 2140, 10.2337/dc12-0060 · DOI · Paper page
  11. Mashhood, 2013, Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging, J Magn Reson Imaging, 37, 1359, 10.1002/jmri.23928 · DOI · Paper page
  12. Dmitrienko, 2008, A note on tree gatekeeping procedures in clinical trials, Stat Med, 27, 3446, 10.1002/sim.3307 · DOI
  13. Luo, 2013, Analysis of hypoglycemic events using negative binomial models, Pharm Stat, 12, 233, 10.1002/pst.1576 · DOI
  14. Vora, 2014, Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials, Diabetes Ther, 5, 435, 10.1007/s13300-014-0076-9 · DOI · Paper page
  15. Hollander, 2008, A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes, Clin Ther, 30, 1976, 10.1016/j.clinthera.2008.11.001 · DOI · Paper page
  16. Raskin, 2009, Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes, Diabetes Metab Res Rev, 25, 542, 10.1002/dmrr.989 · DOI · Paper page
  17. Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
  18. Morrow, 2013, LY2605541 (LY) exhibits a flatter glucodynamic profile than insulin glargine (GL) at steady state in subjects with type 1 diabetes (T1D), Diabetes, 62, A233
  19. Lingvay, 2007, Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes, J Diabetes Complications, 21, 137, 10.1016/j.jdiacomp.2007.02.005 · DOI
  20. Chaudhuri, 2012, Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis, Diabetes Metab Res Rev, 28, 258, 10.1002/dmrr.1305 · DOI
  21. Gerstein, 2006, A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study, Diabet Med, 23, 736, 10.1111/j.1464-5491.2006.01881.x · DOI · Paper page
  22. Liu, 2012, Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study, Atherosclerosis, 224, 521, 10.1016/j.atherosclerosis.2012.07.042 · DOI · Paper page
  23. Blevins, 2015, Superior HbA1c reduction with basal insulin peglispro (BIL) vs insulin glargine (GL) and preprandial insulin lispro in a double-blind study in patients (pts) with type 2 diabetes (T2D): IMAGINE 4, Diabetes, 64, A250

Cited by

See all 82

Metadata

Authors
Buse, J. B., Rodbard, H. W., Trescoli Serrano, C., Luo, J., Ivanyi, T., Bue-Valleskey, J., Hartman, M. L., Carey, M. A., & Chang, A. M.
Venue
Diabetes Care
Published
2015-11-17
Volume
39
Issue
1
Pages
92-100
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2173136480
Cited by
82
References
9
FWCI
13.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. https://app.cochat.ai/papers/10.2337/dc15-1531
The paper
Buse, J. B., Rodbard, H. W., Trescoli Serrano, C., Luo, J., Ivanyi, T., Bue-Valleskey, J., Hartman, M. L., Carey, M. A., & Chang, A. M. (2016). Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. Diabetes Care. https://doi.org/10.2337/dc15-1531

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.